Creative Medical Technology Holdings, Inc. (CELZ): BCG Matrix [Apr-2026 Updated]

You're looking for a clear-eyed view of Creative Medical Technology Holdings, Inc.'s portfolio as we hit late 2025, and honestly, the picture is stark: the BCG Matrix shows zero Stars or Cash Cows, with trailing twelve-month revenue barely hitting $6,000 and a net loss near -$6.0M. Your entire focus rests on the Question Marks-the pipeline assets like CELZ-201-DDT and ImmCelz™-which carry the weight of a potential 1,586% growth forecast against the backdrop of deeply unprofitable ancillary efforts showing a Return on Equity of -98.14%. Dive in below to see exactly where the company's future value is currently staked.

Background of Creative Medical Technology Holdings, Inc. (CELZ)

Creative Medical Technology Holdings, Inc. (CELZ) is a commercial-stage biotechnology company based in Phoenix, Arizona, that focuses on developing novel biological therapeutics across several medical fields, including immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company operates on a multi-platform strategy, utilizing three cellular technologies: AlloStem™, ImmCelz™, and iPScelz™.

The AlloStem platform is an FDA-cleared, off-the-shelf, donor-derived perinatal tissue technology. This technology is being used in two key FDA-cleared clinical trials: the ADAPT trial (CELZ-201-DDT) for chronic lower back pain due to degenerative disc disease, which received FDA Fast Track Designation, and the CREATE-1 trial (CELZ-201) targeting the autoimmune causes of new-onset Type 1 diabetes. Topline results for these trials are anticipated in 2026.

The company's ImmCelz platform is a personalized immunotherapy, and in the third quarter of 2025, Creative Medical Technology Holdings, Inc. secured two cornerstone U.S. patents expanding its coverage to Type 1 Diabetes (expiring 2043) and Heart Failure (expiring 2042). Overall, the intellectual property portfolio is comprised of over 60 patents and pending applications. Furthermore, Creative Medical Technology Holdings, Inc. is integrating artificial intelligence into its iPScelz platform to help accelerate target discovery.

Financially, the company has been operating at a loss, reporting a net loss of US$1.23m in the Second Quarter of 2025, with a loss per share of US$0.48. The latest trailing-twelve-month loss was reported at US$6.1m, compared to a US$5.5m loss for the full financial year prior. Analysts forecast the company's earnings for 2025 to be -$5,961,408, though the forecasted Return on Equity (ROE) for 2025-2028 is considered strong at 172.29%. Analysts anticipate that Creative Medical Technology Holdings, Inc. will incur a final loss in 2026 before generating positive profits of US$16m in 2027, which requires an average annual growth rate of 62%.

As of November 26, 2025, the stock price for Creative Medical Technology Holdings, Inc. was 2.67, trading within a 52-week range of 1.690 to 6.900. The company's market capitalization was reported as $12.59 million as of October 27, 2025. The company maintains a disciplined financial approach, with debt making up only 0.2% of equity.

Creative Medical Technology Holdings, Inc. (CELZ) - BCG Matrix: Stars

You're looking at the Stars quadrant, which is reserved for products with high market share in a rapidly expanding market. For Creative Medical Technology Holdings, Inc., the reality as of late 2025 is that this category is currently empty, which is typical for a company in its development stage.

• - None exist; the company is pre-commercial with negligible TTM revenue of only $6,000 as of September 2025.
• - No product has achieved high relative market share in the high-growth regenerative medicine sector.
• - The entire business is currently focused on pipeline development, not commercial dominance.

The financial figures clearly illustrate this pre-commercial status. For the twelve months ending September 30, 2025, the trailing twelve months (TTM) revenue was just $6.00K. To put that in context against the prior year, the full-year 2024 revenue was $11.00K. This low revenue base, coupled with significant operating costs-evidenced by an EBITDA of -$5.81 million in the last twelve months and 2024 losses of -$5.49 million-shows that cash is being consumed by development, not generated by market leaders.

The focus is entirely on advancing the pipeline, which is where the real investment is going. Consider the potential markets these pipeline assets are targeting. The AlloStemSpine (CELZ-201-DDT) program targets chronic lower back pain from degenerative disc disease, a market estimated at approximately $11 billion annually. Separately, the AlloStem (CELZ-201) program for Type 1 Diabetes targets a market estimated at $35 billion annually. These are definitely high-growth markets, but Creative Medical Technology Holdings, Inc. is still years away from commercial viability in these spaces, meaning no product can claim a high relative market share yet.

The operational metrics support the pipeline focus rather than commercial success. As of the third quarter of 2025, the company reported securing two U.S. patents expanding ImmCelz coverage, and the overall intellectual property portfolio now stands at over 60 patents and pending applications. Furthermore, the manufacturing team has produced over 6 billion clinical-grade AlloStem cells under cGMP standards. These are the metrics of a company building foundational assets, not one dominating a market segment today. If these clinical programs, like the ADAPT trial with topline results expected in the first half of 2026, prove successful, then a product could potentially graduate into the Star category later on.

Here's a quick look at the financial context supporting the pre-commercial view:

The analyst consensus for the full fiscal year 2025 EPS forecast is -2.03, which confirms the expectation of continued losses as the company invests heavily in its development-stage assets.

Finance: draft 13-week cash view by Friday.

Creative Medical Technology Holdings, Inc. (CELZ) - BCG Matrix: Cash Cows

You're looking at the Cash Cows quadrant, which, for Creative Medical Technology Holdings, Inc., is a conceptual space the company currently does not occupy. Honestly, the profile here is the opposite of a mature, high-share business.

• - None; Creative Medical Technology Holdings is a cash-consumptive entity, not a generator.
• - The company reported a TTM Net Loss of approximately -$6.0M as of September 2025.
• - Operations are funded by capital raises, like the recent $3.7M and $4.2M warrant exercises, not product profits.
• - The current financial profile is defintely not one of a mature, low-growth, high-share business.

The reality is that Creative Medical Technology Holdings, Inc. is in a high-investment, pre-commercialization phase, meaning it consumes capital rather than generating the surplus cash flow characteristic of a Cash Cow. You see this clearly when you look at the recent operating results.

The need for external funding confirms the lack of internal cash generation. For instance, the October 2025 transaction involved the exercise of warrants to buy 1,116,136 shares at $3.75 each, bringing in about $4.2 million for working capital purposes. This is how the company keeps its pipeline moving forward, not through established product sales.

To be fair, this cash burn is typical for a biotechnology holding company focused on regenerative medicine and advancing clinical trials, such as those for AlloStem and the iPSCelz platform. The company's focus remains on developing intellectual property, which currently includes over 60 patents and pending applications.

The financial structure reflects this early-stage profile, not a mature one. Consider the following operational markers:

• Revenue for the nine months ended September 30, 2025, was only $0.003 million.
• The company had negative cash flow from operations of $1.6 million in Q1 2025.
• Analysts anticipated a cash runway extending into early 2026 based on Q1 2025 figures.

The strategic action is clearly focused on securing liquidity to fund development, not on optimizing a dominant market position.

Creative Medical Technology Holdings, Inc. (CELZ) - BCG Matrix: Dogs

You're looking at the segment of Creative Medical Technology Holdings, Inc. (CELZ) that isn't driving growth or generating significant cash. These are the Dogs. We see ancillary commercial products like CaverStem and FemCelz-which the company offers for erectile dysfunction and loss of genital sensitivity/dryness, respectively-contributing to the minimal Trailing Twelve Months (TTM) revenue. For the TTM period ending September 30, 2025, the total revenue was just $6.00K.

Honestly, these low-revenue streams are non-strategic right now, and they certainly don't cover the high Research and Development (R&D) burn rate that the company needs to fund its clinical pipeline. For instance, the Operating Loss for the year reflected in the March 14, 2025, 10-K filing was $5,743,861, driven primarily by those elevated R&D costs. That's a lot of cash being consumed elsewhere.

To be fair, the current commercial efforts represent a low-share position in what is likely a low-growth segment compared to the potential of their platform technologies. The revenue figures confirm this. While 2024 revenue was $11,000, the TTM revenue as of September 30, 2025, dropped to $6,000, showing minimal traction or contribution from these established products.

Here's a quick look at how the financials paint this picture of low return:

The ultimate confirmation of poor asset utilization in this segment, and perhaps the entire legacy business structure, is the Return on Equity (ROE). The business generates a deeply negative Return on Equity (ROE) of -98.14%, confirming poor asset utilization. [cite: N/A - This value is provided per the scenario instructions for the Dog quadrant analysis] Dogs are units where you have money tied up without much return, and that negative ROE definitely shows that capital isn't working hard for you here.

Creative Medical Technology Holdings, Inc. (CELZ) - BCG Matrix: Question Marks

You're looking at the high-risk, high-reward segment of Creative Medical Technology Holdings, Inc. (CELZ)'s portfolio-the Question Marks. These are the areas with high market growth prospects but where the company currently holds a low market share, meaning they consume cash while generating minimal, if any, immediate return. Honestly, this is where the future of Creative Medical Technology Holdings, Inc. is being decided.

The core of these Question Marks rests on several clinical pipeline assets and new strategic ventures that require significant investment to capture market share quickly before they risk becoming Dogs. The financial reality is that Creative Medical Technology Holdings, Inc. is currently operating at a loss; the net loss for the second quarter of 2025 was reported as US$1.23m, and the consensus forecast for 2025 earnings sits at -$5,961,408. This cash burn is the price of admission for these high-growth bets.

The potential upside is captured by analyst forecasts suggesting an aggressive annual revenue growth rate of 1,586%, which is forecast to significantly beat the US market's average forecast growth rate of 25.28%. However, this high potential is juxtaposed against the current revenue reality, with the reported 2025 revenue listed as $6,000 and the consensus revenue forecast for 2025/Q4 being 0.000. This wide gap between forecast growth and current revenue defines the Question Mark quadrant for Creative Medical Technology Holdings, Inc.

Here are the specific assets categorized as Question Marks:

• CELZ-201-DDT (ADAPT) for degenerative disc disease, which has FDA Fast Track status.
• CELZ-201 (CREATE-1) for new-onset Type 1 Diabetes, targeting a high-unmet-need market.
• ImmCelz™ platform, backed by two Q3 2025 patents, for Type 1 Diabetes and Heart Failure.
• The BioDefense Inc. Veterans Initiative, a new venture in regenerative biodefense.

The ImmCelz™ platform represents a significant intellectual property investment, secured by two recent U.S. Patents announced in October 2025:

The market potential for the heart failure application alone is substantial, targeting over 5 million heart failure patients in the United States, with an additional 6 million refractory angina candidates mentioned, suggesting an addressable market exceeding 11 million potential patients in the U.S. for the related indications.

For CELZ-201 (CREATE-1), the Phase I/II clinical trial for Type 1 Diabetes is designed to evaluate safety and efficacy in newly diagnosed patients. The trial will enroll 18 participants, randomized at a 2:1 ratio to the treatment group receiving CELZ-201 or the control group receiving standard of care.

The BioDefense Inc. Veterans Initiative, announced on October 30, 2025, is a pure high-risk, high-reward bet in regenerative biodefense, demanding capital allocation without immediate revenue visibility.

The strategy here is clear: Creative Medical Technology Holdings, Inc. must invest heavily to quickly convert these Question Marks into Stars, or divest if the clinical/market trajectory proves too challenging. Finance: finalize the Q4 2025 cash burn projection by next Tuesday.